Form 4: 4D Molecular Therapeutics Director Susannah Gray Receives Stock Option Grant

Susannah Gray, a Director at 4D Molecular Therapeutics, Inc., was granted 22,500 stock options with an exercise price of $4.15 as part of the company's non-employee director compensation program.

Summary

• Susannah Gray, a Director of 4D Molecular Therapeutics, Inc. (FDMT), was granted 22,500 stock options.
• The stock options have an exercise price of $4.15 per share.
• The grant was made automatically pursuant to the terms of the Company's non-employee director compensation program.
• The options will vest and become exercisable with respect to one-third (1/3) of the total shares on June 17, 2026.
• The remaining shares will vest in equal monthly installments thereafter, subject to Ms. Gray's continued service to the Issuer, until fully vested on June 17, 2028.
• The stock options will also vest in full upon the consummation of a Change in Control, as defined in the 2020 Incentive Award Plan.
• The expiration date for these stock options is June 16, 2035.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a routine compensation event, it signifies continued alignment of a director's interests with the company's long-term performance and shareholder value, which is generally viewed favorably.

Positives

• The grant of stock options aligns the interests of Director Susannah Gray with those of the company's shareholders, incentivizing long-term value creation.
• The option grant is part of a pre-established, automatic non-employee director compensation program, indicating a structured and transparent approach to executive incentives.

Risks

• The vesting of the stock options is contingent upon the Reporting Person's continued service to the Issuer through each vesting date, meaning the options could be forfeited if service ceases prematurely.
• While a 'Change in Control' clause provides for accelerated vesting, it also introduces a dependency on external corporate events for full realization of the options.

Future Outlook

The stock option grant is designed to incentivize the director's long-term commitment and contribution to the company's performance, with vesting tied to continued service over the next three years and potential acceleration upon a change in control.

Management Comments

• The stock option was 'Automatically granted pursuant to the terms of the Company's non-employee director compensation program.'
• The stock option 'vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028.'
• Additionally, 'the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).'

Industry Context

The grant of stock options to non-employee directors is a common practice across various industries, particularly in biotechnology and high-growth sectors, serving as a key component of compensation to align director interests with shareholder value and encourage long-term commitment.

Comparison to Industry Standards

• Stock options are a standard component of non-employee director compensation packages in publicly traded companies, especially within the biotechnology sector, to attract and retain qualified board members.
• The vesting schedule, which includes an initial cliff vesting followed by monthly installments over a multi-year period, is a common structure designed to ensure continued service and long-term alignment.
• The inclusion of a 'Change in Control' acceleration clause is also a typical feature in equity compensation plans, providing protection and incentive for directors during significant corporate transactions.

Corporate Governance

Related Party Transactions

• The grant of stock options to Susannah Gray, a Director of 4D Molecular Therapeutics, Inc., constitutes a related party transaction as it involves a transaction between the company and a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases above the exercise price.
• Employees: No direct impact on employees, but it reflects the company's overall compensation philosophy for key personnel.

Next Steps

• Director Susannah Gray's continued service to 4D Molecular Therapeutics, Inc. is required for the stock options to vest according to the schedule.
• The company will continue to monitor and report on insider transactions as required by SEC regulations.

Key Dates

Keywords

4D Molecular Therapeutics, FDMT, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biotechnology, Corporate Governance